Literature DB >> 8798258

Neutrophil elastase/alpha 1-proteinase inhibitor complex levels decrease in plasma of cystic fibrosis patients during long-term oral beta-carotene supplementation.

B M Winklhofer-Roob1, S E Schlegel-Haueter, G Khoschsorur, M A van't Hof, S Suter, D H Shmerling.   

Abstract

Lung inflammation in cystic fibrosis (CF) is associated with an increased release from activated neutrophils of oxidants and proteinases. Free radical generation is not efficiently neutralized, and the major anti-proteinase, alpha 1-proteinase inhibitor (alpha 1-PI) is thought to be oxidatively inactivated. We hypothesized that enhanced antioxidant protection could represent an additional long-term strategy to attentuate the host inflammatory response. The effect on plasma neutrophil elastase/alpha 1-PI (NE/alpha 1-PI) complex levels (as a marker of lung inflammation) and plasma malondialdehyde concentrations (as a marker of lipid peroxidation) of additional oral beta-carotene supplementation was studied in 33 CF patients who had already received long-term vitamin E supplementation. In the presence of a more than 10-fold increase in plasma beta-carotene concentrations (mean +/- SEM) (0.09 +/- 0.01 to 1.07 +/- 0.19 mumol/L; p < 0.0001), a small increase in plasma alpha-tocopherol concentrations (23.8 +/- 1.31 to 28.4 +/- 1.81 mumol/L; p = 0.02), and a more than 50% decrease in plasma malondialdehyde concentrations (1.00 +/- 0.07 to 0.46 +/- 0.03 mumol/L; p < 0.0001), plasma NE/alpha 1-PI complex levels decreased from 102.2 +/- 16.0 to 83.0 +/- 10.4 micrograms/L; (p = 0.02). Plasma retinol concentrations increased (1.05 +/- 0.06 to 1.23 +/- 0.07 mumol/L; p = 0.0001) due to conversion of beta-carotene to retinol, which could have contributed to the decrease in NE/alpha 1-PI complex levels. Based on these results, we speculate that efficient antioxidant supplementation could attenuate lung inflammation in CF.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8798258     DOI: 10.1203/00006450-199607000-00022

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  9 in total

Review 1.  Redox balance in cystic fibrosis.

Authors:  Assem G Ziady; Jason Hansen
Journal:  Int J Biochem Cell Biol       Date:  2014-03-20       Impact factor: 5.085

2.  Elevated plasma levels of F2 alpha isoprostane in cystic fibrosis.

Authors:  C E Collins; P Quaggiotto; L Wood; E V O'Loughlin; R L Henry; M L Garg
Journal:  Lipids       Date:  1999-06       Impact factor: 1.880

3.  Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis.

Authors:  S Renner; R Rath; P Rust; S Lehr; T Frischer; I Elmadfa; I Eichler
Journal:  Thorax       Date:  2001-01       Impact factor: 9.139

4.  Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland, November 11-12, 2003.

Authors:  André M Cantin; Terry B White; Carroll E Cross; Henry Jay Forman; Ronald J Sokol; Drucy Borowitz
Journal:  Free Radic Biol Med       Date:  2006-09-29       Impact factor: 7.376

5.  Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis.

Authors:  Matthew N Hurley; Sherie Smith; Douglas L Forrester; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2020-07-16

Review 6.  Anti-inflammatory therapies for cystic fibrosis-related lung disease.

Authors:  David P Nichols; Michael W Konstan; James F Chmiel
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

Review 7.  Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis.

Authors:  Matthew N Hurley; Douglas L Forrester; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

8.  Lutein, zeaxanthin, macular pigment, and visual function in adult cystic fibrosis patients.

Authors:  Christine Schupp; Estibaliz Olano-Martin; Christina Gerth; Brian M Morrissey; Carroll E Cross; John S Werner
Journal:  Am J Clin Nutr       Date:  2004-06       Impact factor: 7.045

Review 9.  Antioxidant supplementation for lung disease in cystic fibrosis.

Authors:  Oana Ciofu; Sherie Smith; Jens Lykkesfeldt
Journal:  Cochrane Database Syst Rev       Date:  2019-10-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.